1. Anti-infection
  2. HIV
    Reverse Transcriptase
    HBV

Tenofovir Disoproxil Fumarate (Synonyms: Tenofovir DF)

Cat. No.: HY-13782 Purity: 99.46%
Data Sheet SDS Handling Instructions

Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

For research use only. We do not sell to patients.
Tenofovir Disoproxil Fumarate Chemical Structure

Tenofovir Disoproxil Fumarate Chemical Structure

CAS No. : 202138-50-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
50 mg $100 In-stock
100 mg $150 In-stock
200 mg $200 In-stock
500 mg $400 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Tenofovir Disoproxil Fumarate:

    Tenofovir Disoproxil Fumarate purchased from MCE. Usage Cited in: J Neuroimmune Pharmacol. 2017 Jul 22.

    TDF/FTC/RAL combined medication induces mouse NPC apoptosis in vitro. Mouse NPCs are treated with either DMSO or TDF/FTC/RAL for 8 h. Cleaved Caspase-3 levels are determined by Western blotting.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

    In Vitro

    Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC50 values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage[1]. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1BaL and X4-tropic HIV-1IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1BaL, and is not toxic to PBMCs[2].

    In Vivo

    Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice[3]. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection[4].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT02479880 Gilead Sciences Hepatitis B July 30, 2015 Phase 4
    NCT00507507 Gilead Sciences Chronic Hepatitis B September 2007 Phase 2
    NCT00352053 Gilead Sciences HIV Infections June 2006 Phase 3
    NCT02039362 Hopital Lariboisière Pregnancy|HBV July 2012 Phase 4
    NCT01334567 Gilead Sciences Hepatitis B August 2010 Phase 2
    NCT00648817 Gilead Sciences HIV Infections July 2006 Phase 4
    NCT00036634 Gilead Sciences HIV Infections March 2002 Phase 1|Phase 2
    NCT01651403 Gilead Sciences Chronic Hepatitis B Infection December 2012 Phase 3
    NCT00078182 National Institute of Allergy and Infectious Diseases (NIAID)|NCHADS - Ministry of Health of Cambodia|Kirby Institute HIV Infections|HIV Seronegativity Phase 2|Phase 3
    NCT00528957 Gilead Sciences HIV Infections December 28, 2006 Phase 3
    NCT00391638 French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Roche Pharma AG|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Hepatitis B|HIV Infections January 2007 Phase 2|Phase 3
    NCT00024986 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) HIV Infection October 2001 Phase 1
    NCT01737359 RFS Pharma, LLC Human Immunodeficiency Virus Infection December 2012 Phase 2
    NCT00307489 Gilead Sciences Chronic Hepatitis B March 2006 Phase 2
    NCT00106379 Gilead Sciences HIV Infections October 2004 Phase 4
    NCT00298363 Gilead Sciences Chronic Hepatitis B April 2006 Phase 2
    NCT00647946 Gilead Sciences Lipodystrophy February 2003 Phase 2
    NCT00365612 Gilead Sciences|Bristol-Myers Squibb HIV Infections July 2006 Phase 4
    NCT01855867 Kenneth H. Mayer, MD|Gilead Sciences|Fenway Community Health Human Immunodeficiency Virus May 2013 Phase 4
    NCT00038220 Abbott HIV Infections July 2000 Phase 2
    NCT00323544 Gilead Sciences HIV Infections October 2004 Phase 3
    NCT00115609 French National Agency for Research on AIDS and Viral Hepatitis HIV Infections|Tuberculosis January 2006 Phase 3
    NCT02180438 University of Washington|Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann|Gilead Sciences HIV-2 Infection September 2014 Phase 4
    NCT00043966 Abbott HIV Infections July 2002 Phase 3
    NCT00221286 University Hospital, Bonn|Hoffmann-La Roche Chronic Hepatitis B|HIV Infections September 2004 Phase 3
    NCT01602822 Kenneth H. Mayer, MD|Bristol-Myers Squibb|Gilead Sciences|Abbott|Fenway Community Health HIV February 2012 Phase 4
    NCT00234910 Abbott HIV Infection January 2005 Phase 3
    NCT00552240 Boehringer Ingelheim HIV Infections September 2007 Phase 4
    NCT00863668 University of Minnesota - Clinical and Translational Science Institute|Merck Sharp & Dohme Corp. HIV Infection|HIV Infections March 2009
    NCT00036452 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 1.5735 mL 7.8677 mL 15.7354 mL
    5 mM 0.3147 mL 1.5735 mL 3.1471 mL
    10 mM 0.1574 mL 0.7868 mL 1.5735 mL
    Cell Assay
    [1]

    Cells are plated into 48-well tissue culture plates (39,000 cells/mL) and allowed to grow for 48 h followed by treatment with vehicle or Tenofovir. Following the treatment period, cell viability is assessed using the MTT assay. The MTT assay relies on the conversion of tetrazolium dye 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by NAD(P)H-dependent oxidoreductases. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    Tenofovir Disoproxil Fumarate is prepared in a placebo control.

    Twenty adult chronic WHV carrier woodchucks are stratified equally by age, sex, body weight, and serum GGT activity into five treatment groups consisting of four animals each: (i) Tenofovir Disoproxil Fumarate at 15.0 mg/kg once per day, (ii) Tenofovir Disoproxil Fumarate at 5.0 mg/kg/day, (iii) Tenofovir Disoproxil Fumarate at 1.5 mg/kg/day, (iv) Tenofovir Disoproxil Fumarate at 0.5 mg/kg/day, and (v) a placebo control. The woodchucks are treated daily for 4 weeks and observed for an additional 12 weeks following cessation of drug treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tenofovir Disoproxil Fumarate
    Cat. No.:
    HY-13782
    Quantity: